|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.60 CAD | +0.07% |
|
+1.25% | +14.69% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 167M 119M 104M 95.92M 88.62M 11.4B 170M 1.14B 449M 5.58B 446M 436M 19.23B | P/E 2026 * |
16.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 167M 119M 104M 95.92M 88.62M 11.4B 170M 1.14B 449M 5.58B 446M 436M 19.23B | EV / Sales 2026 * |
2.42x | EV / Sales 2027 * | 2.03x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 week | +1.18% | ||
| Current month | +0.62% | ||
| 1 month | +4.59% | ||
| 3 months | -1.95% | ||
| 6 months | +12.23% | ||
| Current year | +14.61% |
| 1 week | 14.5 |  | 14.72 |
| 1 month | 13.8 | | 14.72 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.41 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-29 | Option | Executive/Senior Manager | 2,170 | 0.0190% | ||
| 06-29 | Option | -1,884 | 0.0165% | |||
| 06-29 | Option | -800 | 0.0070% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +1.18% | +25.24% | +91.97% | 118M | |
| -2.42% | -6.49% | +44.54% | +157.05% | 1,054B | |
| -1.64% | -5.37% | +61.26% | +58.19% | 621B | |
| -1.05% | -3.59% | +28.19% | +80.51% | 438B | |
| -1.12% | -3.68% | +26.89% | +20.58% | 325B | |
| -1.73% | -3.45% | +26.95% | +44.09% | 281B | |
| -1.95% | -13.92% | +15.96% | +19.76% | 262B | |
| -1.45% | -2.37% | -27.87% | -39.87% | 219B | |
| -1.29% | -3.21% | +19.94% | +56.65% | 195B | |
| -1.01% | -4.56% | +16.10% | +68.60% | 163B | |
| Average | -1.41% | -1.52% | +23.72% | +55.75% | 355.63B | |
| Weighted average by Cap. | -1.75% | -1.69% | +33.23% | +77.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.09M 42.9M 39.66M 36.64M 4.72B 70.25M 473M 186M 2.31B 184M 180M 7.95B | 82.3M 58.55M 51.17M 47.3M 43.7M 5.62B 83.79M 564M 221M 2.75B 220M 215M 9.48B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | $14.60 | +0.07% | 7,218 |
| 26-07-13 | $14.59 | -0.07% | 2,274 |
| 26-07-10 | $14.60 | -0.82% | 4,970 |
| 26-07-09 | $14.72 | +0.55% | 11,275 |
| 26-07-08 | $14.64 | +1.53% | 3,970 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.59CAD
Average target price
18.00CAD
Spread / Average Target
+23.37%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
